Researcher

Joe Yeong’s main research focus is to understand and overcome the resistance of cancer immunotherapy through the use of advanced technologies and artificial intelligence (AI). As an immunopathologist, his key vision is to bridge the work of immunologists and pathologists. Yeong is a pioneer in spatial technologies and a Stanford/Elsevier Top 2% Scientist with over 130 published papers in the field, and has translated assays to clinical settings. His works on cancer immunology have been included in several national and international funded studies as well as industry-sponsored projects.

As a committee member in the World Immunotherapy Council (WIC) under the Society for Immunotherapy of Cancer (SITC), Yeong is among the organisers of the 2019, 2023 and 2025 WIC Global Symposia, as well as WIC multiplex IF expert consensus meetings. In 2023, he co-founded the WIC Asian Chapter for promoting tumour immunology and advancing cancer immunotherapy education, information and research across Asia.

Yeong serves as a founding Program Chair of CLINICCAI-MICCAI, one of the world’s largest AI medical imaging conferences; as a founding board member of MICCAI SIG-ComPath; as the Secretary (Executive) of the Singapore Society of Oncology – Cancer Immunotherapy Consortium (SSO-CIC); as a Co-lead in Education/Diagnostics of the Singhealth Duke-NUS Cell Therapy Centre; and as Advisor (Spatial Technology) for the Cancer Discovery Hub at the National Cancer Centre Singapore.

Yeong holds editorial roles in Springer Nature, Journal for Immunotherapy of Cancer (JITC) and Journal of Clinical Oncology (JCO), and is Chief Editor at World Scientific. He is also a regular reviewer for JITC, Modern Pathology, Lancet, Nature and other leading journals.